Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Acer crawled time : 14:01 save search
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
Published: 2021-02-11 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 1.47%
H: 10.6%
C: -3.86%
results trial topline
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
Published: 2020-12-22 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.38%
H: 0.75%
C: -3.01%
urea trial enroll
Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden
Published: 2020-12-17 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.0%
H: 8.61%
C: 0.41%
syndros
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.